SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...
LONDON, July 4, 2025 /PRNewswire/ -- FinSei (previously AltPay.uk), an innovative fintech company specializing in secure, seamless payment services, has announced a strategic partnership with...
LONDON, July 4, 2025 /PRNewswire/ -- FinSei (previously AltPay.uk), an innovative fintech company specializing in secure, seamless payment services, has announced a strategic partnership with...
Las Vegas, NV, July 03, 2025 (GLOBE NEWSWIRE) -- Area 52, a vanguard in cannabinoid science and botanical engineering, today announced the debut of its 2025 THCA Snow Caps collection, a groundbreaking line of premium hemp flower completely enveloped in pure THCA diamonds. Engineered to “Alienize Your Mind,” these crystalline-coated buds represent a new frontier in potency and sensory experience for the discerning cannabis connoisseur.
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...
SINGAPORE, July 4, 2025 /PRNewswire/ -- XL Ventures Pte Ltd, a Singapore-headquartered climate tech focused company, has received In-Principle Approval from the Monetary Authority...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.
TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.